InsidersTradesSigma
Track the Lomond Therapeutics Holdings, Inc. stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 5 November 2024 (C). Among the most active insiders: Savchuk Nikolay. The full history is openly available.
Analysts rate Lomond Therapeutics Holdings, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Lomond Therapeutics Holdings, Inc. is a company listed on the XNAS market, focused on developing innovative therapies. It specializes in research and development of therapeutic solutions for specific diseases.